Overview

AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This is a double-masked, randomized, controlled study assessing the safety and ocular hypotensive efficacy of two AR 12286/travoprost fixed-dose combination products compared to Travatan® Z in patients with elevated intraocular pressure
Phase:
Phase 2
Details
Lead Sponsor:
Aerie Pharmaceuticals
Treatments:
Travoprost